Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 6/20 | 0.58 |
| ▸ | SYK | P43405 | 6/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1944222 | 0.91 | PRKCQ (0.48) | PRKCQSYKCSNK2A2CSNK2A1EGFR | |
| SCHEMBL1943804 | 0.89 | PRKCQ (0.62) | PRKCQSYKEGFRBTKKDR | |
| SCHEMBL1943251 | 0.86 | PRKCQ (0.59) | PRKCQSYKEGFRBTKKDR | |
| SCHEMBL1944229 | 0.86 | PRKCQ (0.77) | PRKCQSYKEGFRBTKAURKB | |
| SCHEMBL1944272 | 0.86 | PRKCQ (0.59) | PRKCQSYKEGFRBTKKDR | |
| SCHEMBL1944328 | 0.85 | PRKCQ (0.59) | PRKCQSYKEGFRBTKKDR | |
| SCHEMBL1944315 | 0.82 | PRKCQ (0.62) | PRKCQSYKEGFRBTK | |
| SCHEMBL3505933 | 0.82 | PRKCQ (0.59) | PRKCQSYKCSNK2A2CSNK2A1EGFR | |
| SCHEMBL1946062 | 0.81 | PRKCQ (0.54) | PRKCQSYKEGFRBTKKDR | |
| SCHEMBL1944983 | 0.81 | PRKCQ (0.56) | PRKCQSYKEGFRBTKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507227-B1 | TETRAZOLONES AS PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2014-10-08 | — | — | EP | claimed |
| US-20110130415-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. | 2011-06-02 | — | — | US | claimed |
| US-9732070-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732070-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732070-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170152246-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2017-06-01 | — | — | US | disclosed |
| US-20170152246-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2017-06-01 | — | — | US | disclosed |
| US-20170152246-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2017-06-01 | — | — | US | disclosed |
| EP-2507227-B1 | TETRAZOLONES AS PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2507227-B1 | TETRAZOLONES AS PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2014-10-08 | — | — | EP | disclosed |
| WO-2011068898-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20110130415-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. | 2011-06-02 | — | — | US | disclosed |
| US-20110130415-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. | 2011-06-02 | — | — | US | disclosed |
| US-20110130415-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130415-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | PRKCQ 5/4885SYK 600/4885CSNK2A2 158/4885 |
| US-20170152246-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | PRKCQ 5/4885SYK 600/4885CSNK2A2 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.